RACE -2.81V -0.03TDG 2.77WDC -4.25MRVL -0.64NVDA -0.92CCEC.TO 0SDE.TO -0.16
Danaher Corp. (DHR)

NYSE:DHR

Danaher Corp. (DHR)

221.05
-0.04 (0.02%)
as of Sep 23, 2026, 3:44:20 pm Market Open.
96 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
PARTIAL SELL

Danaher Corp.(DHR)

Dec 31, 2021
Likes the life sciences and diagnostics exposure here. DHR is a serial acquirer, starting to divest businesses. You can take some profits and buy Stryker.
Photo of Shannon Saccocia, CIO, Boston PrivateShannon Saccocia, CIO, Boston PrivateUnlock Rating
$330.69

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
TOP PICK

Danaher Corp.(DHR)

Nov 08, 2021
A conglomerate in the healthcare space. They have done exceedingly well during COVID. They integrated into genomic medicine. (Analysts’ price target is $340.03)
Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$301.35

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
BUY

Danaher Corp.(DHR)

Apr 16, 2021
They report Thursday. They have a high-growth healthcare business that they partly picked up from GE for a song. He expects a great quarter.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$243.06

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
DON'T BUY

Danaher Corp.(DHR)

Mar 19, 2021
A diversified industrial company in the life science and diagnostic services business. Has grown through acquisitions. Has made 2 dozens acquisitions in the past year. Bought GE's biopharma business. Relatively expensive at 40x earnings. Does not warrant this type of price tag. Nothing wrong but a little expensive for him.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$221.06

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
COMMENT

Danaher Corp.(DHR)

Feb 10, 2021

DHR vs. TMO vs. WAT WAT not performing as well as Thermo Fisher or Danaher. Cash from operations has been flat in the last 4 years, whereas the other two have doubled, which is reflected in the stock price. Market share, operating margins, and pricing power impact the business model. Compare these when assessing competitors in an industry.

Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$237.97

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
COMMENT

Danaher Corp.(DHR)

Jan 08, 2021

A fine long-term performer. They bought a biopharma asset from GE and will report on it in on Wednesday.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$243.49

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
PAST TOP PICK

Danaher Corp.(DHR)

Sep 16, 2020

(A Top Pick Oct 28/19, Up 54%) Covid is impacting them. They bought GE pharma division, and the timing couldn't be better. Grown dividend by 28% over the last 5 years, paying down debt.

Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$208.11

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
BUY

Danaher Corp.(DHR)

Aug 31, 2020
They produce consumables for drug production, a great company. For the discovery and production of drugs. They're in a unique situation, because their filtration systems also apply to industrial production.
Photo of David FingoldDavid Fingold
Owned
Unlock Rating
$206.35

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
Track your Stocks in your Watch List
WAIT

Danaher Corp.(DHR)

Aug 25, 2020
Has long owned this. It's benefited from COVID, because DHR prrovides testing equipment. Their latest acquisition was huge, from GE's bio-farm unit. DHR is expensive now, but this is good for the long term. Buy only half or a third now and see what happens with volatility in the fall running up the U.S. election.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$207.15

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
WATCH

Danaher Corp.(DHR)

Apr 20, 2020
It is rather like a 3-M, a healthcare services like company, diagnostics, etc. He thinks it is a fabulous company. Maybe you want to hold this for a longer period of time. Margins may be peaking, however. In the US healthcare is tied to employment. The dividend is actually quite small. You want to focus on this in the post-COVID-19 environment.
Photo of Darren SissonsDarren SissonsUnlock Rating
$156.72

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
PAST TOP PICK

Danaher Corp.(DHR)

Feb 07, 2020

(A Top Pick Jan 17/19, Up 54%) A life-sciences companies that also does consumables and mass spectrometers. They recently purchased the GE biopharma section. They have big margins coming into the company. Earnings were higher than their peer group. He has owned this since 2013 and he sees no reason to sell it. He wouldn't enter now with 30x earnings. It works as a core holding since life science has good growth potential.

Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$161.99

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
COMMENT

Danaher Corp.(DHR)

Feb 04, 2020
As a roll-up It was a roll-up, but not now. The new DHR is a producer of filtration systems and single-use consumables that help make biotech drugs. They have a leading market share, supplying most major biotechs around the world. He likes it. Little is built into the numbers now and investors are very conservative about forecasting the biotech drug market.
Photo of David FingoldDavid Fingold
Owned
Unlock Rating
$163.29

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
SELL

Danaher Corp.(DHR)

Jan 13, 2020
They have been a successful franchise and acquisition story. His concern has always been valuation. This is a great company. It should be on your radar. It is too expensive so you should sell it.
Photo of Darren SissonsDarren SissonsUnlock Rating
$159.32

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
PAST TOP PICK

Danaher Corp.(DHR)

Jan 13, 2020
(A Top Pick Oct 28/19, Up 17%) It's up 52% in the past year, but $10,000 returned over 30 years is now $2.3 million!
Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$159.57

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
TOP PICK

Danaher Corp.(DHR)

Oct 28, 2019
A private equity company and a smart acquisitor. They bought GE's biopharma division which added debt to their books, but DHR has done buys like this before, knowing how to pay down debt yet be accretive to earnings. They have spun-off their dental division The dividend has grown 28% annually, though it is small now. Great for the long term. (Analysts’ price target is $152.14)
Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$136.21

Stock price when the opinion was issued

$221.05

As of Sep 23, 2026. Market Open.

Healthcare
Showing 46 to 60 of 73 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO -1.42$285.75
META 16.255$752.85
SYK -2.45$272.64
LYV 0.66$169.84
DPZ 1.175$297.115

Today's Top Picks

RACE -2.81$413.32
V -0.03$362.01
TDG 2.77$1112.42
WDC -4.25$460.35
MRVL -0.64$261.72

Popular Articles

Latest Sell Signals

CPX.TO -0.5$61.8
CPRT -0.115$28.795
UBER -0.37$69.52
DOL.TO -2.53$178.15
BLK -0.05$1066.61

Most Recent Experts

Ernest Wong, Head of Research, Baskin Wealth Management

Ernest Wong, Head of Research, Baskin Wealth Management

Baskin Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jim Lebenthal

Jim Lebenthal

Cerity Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like